Cumberland Pharmaceuticals Inc (CPIX) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Cumberland Pharmaceuticals reported revenue of $44.5M, up 17.6% from $37.9M the year before. Net income was -$2.8M (a -6.4% net margin), or -$0.19 per diluted share. Gross margin was 85.0% and operating margin was -6.3%. Operating activities generated $4.9M of cash, leaving $4.8M of free cash flow. At fiscal year end, Cumberland Pharmaceuticals held $76.8M in total assets against $52.3M in total liabilities, including $11.4M of cash and equivalents.
Open the full interactive Cumberland Pharmaceuticals financials → Quarterly statements, key ratios, valuation history and price charts.
Cumberland Pharmaceuticals Key Stats
| Share Price | $7.17 |
|---|---|
| Market Cap | $107.4M |
| Revenue YoY Growth | +17.6% |
| 52-Week Range | $1.47 – $8.97 |
| Shares Outstanding | 15.0 million (basic, 2026 Q2) |
Cumberland Pharmaceuticals Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $37.4M | $36.0M | $42.0M | $39.6M | $37.9M | $44.5M |
| Cost of Goods Sold | $8.7M | $8.8M | $9.1M | $6.1M | $6.6M | $6.7M |
| Gross Profit | $28.8M | $27.2M | $32.9M | $33.5M | $31.3M | $37.9M |
| Operating Income | -$6.4M | -$7.7M | -$5.7M | -$9.6M | -$6.4M | -$2.8M |
| Pre-Tax Income | -$6.6M | -$5.6M | -$5.6M | -$6.3M | -$6.5M | -$2.8M |
| Income Tax | $55,902 | $34,891 | $68,850 | $45,769 | -$22,669 | $40,256 |
| Net Income | -$3.3M | -$3.5M | -$5.6M | -$6.3M | -$6.5M | -$2.8M |
| Diluted EPS | -$0.22 | -$0.24 | -$0.38 | -$0.44 | -$0.46 | -$0.19 |
Cumberland Pharmaceuticals Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $8.3M | $13.7M | $9.1M | $166,458 |
| Net Income | -$1.9M | -$1.4M | -$3.3M | -$4.3M |
| Diluted EPS | -$0.13 | -$0.10 | -$0.22 | -$0.29 |
Cumberland Pharmaceuticals Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $24.8M | $27.0M | $19.8M | $18.3M | $18.0M | $11.4M |
| Current Assets | $50.0M | $45.7M | $45.9M | $35.7M | $36.5M | $37.1M |
| Total Assets | $96.5M | $84.5M | $92.9M | $81.8M | $75.6M | $76.8M |
| Current Liabilities | $25.7M | $19.3M | $28.6M | $28.0M | $31.6M | $36.7M |
| Total Long-Term Debt | $15.0M | $15.0M | $16.2M | $12.8M | $15.3M | $5.2M |
| Total Liabilities | $49.6M | $41.9M | $57.0M | $52.5M | $53.0M | $52.3M |
| Shareholders' Equity | $47.0M | $42.8M | $36.3M | $29.6M | $22.9M | $24.9M |
Cumberland Pharmaceuticals Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | $5.4M | $6.3M | $8.5M | $6.1M | -$612,186 | $4.9M |
| Cash From Investing | -$1.8M | -$501,893 | -$13.7M | -$105,695 | $57,842 | -$4.7M |
| Cash From Financing | -$7.1M | -$3.6M | -$2.1M | -$7.4M | $196,904 | -$6.7M |
| Free Cash Flow | $5.3M | $6.2M | $8.4M | $5.8M | -$678,647 | $4.8M |
Figures from Cumberland Pharmaceuticals' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Cumberland Pharmaceuticals financials page for every line item.
Cumberland Pharmaceuticals Company Profile
| Ticker | CPIX |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Nashville,, Tennessee |
| Incorporated in | Tennessee |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001087294 |
Frequently Asked Questions
What was Cumberland Pharmaceuticals' revenue in fiscal 2025?
Cumberland Pharmaceuticals (CPIX) reported revenue of $44.5M for fiscal 2025.
What is Cumberland Pharmaceuticals' annual revenue history?
Cumberland Pharmaceuticals' annual revenue by fiscal year: 2020: $37.4M; 2021: $36.0M; 2022: $42.0M; 2023: $39.6M; 2024: $37.9M; 2025: $44.5M.
What was Cumberland Pharmaceuticals' net income in fiscal 2025?
Cumberland Pharmaceuticals reported net income of -$2.8M for fiscal 2025.
What was Cumberland Pharmaceuticals' earnings per share (EPS) in fiscal 2025?
Cumberland Pharmaceuticals' diluted EPS was -$0.19 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Cumberland Pharmaceuticals generate in fiscal 2025?
Cumberland Pharmaceuticals generated $4.8M of free cash flow in fiscal 2025.
What was Cumberland Pharmaceuticals' revenue last quarter?
In its most recent reported quarter (2026 Q2), Cumberland Pharmaceuticals reported revenue of $166,458.
How much debt does Cumberland Pharmaceuticals have?
Cumberland Pharmaceuticals reported $5.2M of long-term debt, including the current portion, at the end of fiscal 2025.
How many shares of Cumberland Pharmaceuticals are outstanding?
Cumberland Pharmaceuticals reported a weighted average of 15.0 million basic shares outstanding in 2026 Q2.
What is Cumberland Pharmaceuticals' market cap?
Based on its latest closing price, Cumberland Pharmaceuticals (CPIX) has a market capitalization of about $107.4M.
When does Cumberland Pharmaceuticals' fiscal year end?
Cumberland Pharmaceuticals' fiscal year end, as registered with the SEC, is December 31.
Where is Cumberland Pharmaceuticals headquartered?
Cumberland Pharmaceuticals lists its business address in Nashville,, Tennessee in its SEC filings.